154 related articles for article (PubMed ID: 38762299)
1. Economic implications of novel regimens for tuberculosis treatment in three high-burden countries: a modelling analysis.
Ryckman TS; Schumacher SG; Lienhardt C; Sweeney S; Dowdy DW; Mirzayev F; Kendall EA
Lancet Glob Health; 2024 Jun; 12(6):e995-e1004. PubMed ID: 38762299
[TBL] [Abstract][Full Text] [Related]
2. Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries.
Lu X; Smare C; Kambili C; El Khoury AC; Wolfson LJ
BMC Health Serv Res; 2017 Jan; 17(1):87. PubMed ID: 28122562
[TBL] [Abstract][Full Text] [Related]
3. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
Schnippel K; Firnhaber C; Conradie F; Ndjeka N; Sinanovic E
Appl Health Econ Health Policy; 2018 Feb; 16(1):43-54. PubMed ID: 28980217
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines.
Gomez GB; Siapka M; Conradie F; Ndjeka N; Garfin AMC; Lomtadze N; Avaliani Z; Kiria N; Malhotra S; Cook-Scalise S; Juneja S; Everitt D; Spigelman M; Vassall A
BMJ Open; 2021 Dec; 11(12):e051521. PubMed ID: 34862287
[TBL] [Abstract][Full Text] [Related]
5. Scaling up target regimens for tuberculosis preventive treatment in Brazil and South Africa: An analysis of costs and cost-effectiveness.
Nsengiyumva NP; Campbell JR; Oxlade O; Vesga JF; Lienhardt C; Trajman A; Falzon D; Den Boon S; Arinaminpathy N; Schwartzman K
PLoS Med; 2022 Jun; 19(6):e1004032. PubMed ID: 35696431
[TBL] [Abstract][Full Text] [Related]
6. Cost comparison of nine-month treatment regimens with 20-month standardized care for the treatment of rifampicin-resistant/multi-drug resistant tuberculosis in Nigeria.
Bada FO; Blok N; Okpokoro E; Dutt S; Akolo C; Dakum P; Abimiku A
PLoS One; 2020; 15(12):e0241065. PubMed ID: 33259492
[TBL] [Abstract][Full Text] [Related]
7. The Impact and Cost-Effectiveness of a Four-Month Regimen for First-Line Treatment of Active Tuberculosis in South Africa.
Knight GM; Gomez GB; Dodd PJ; Dowdy D; Zwerling A; Wells WA; Cobelens F; Vassall A; White RG
PLoS One; 2015; 10(12):e0145796. PubMed ID: 26717007
[TBL] [Abstract][Full Text] [Related]
8. Economic evaluation of shortened, bedaquiline-containing treatment regimens for rifampicin-resistant tuberculosis (STREAM stage 2): a within-trial analysis of a randomised controlled trial.
Rosu L; Madan JJ; Tomeny EM; Muniyandi M; Nidoi J; Girma M; Vilc V; Bindroo P; Dhandhukiya R; Bayissa AK; Meressa D; Narendran G; Solanki R; Bhatnagar AK; Tudor E; Kirenga B; Meredith SK; Nunn AJ; Bronson G; Rusen ID; Squire SB; Worrall E;
Lancet Glob Health; 2023 Feb; 11(2):e265-e277. PubMed ID: 36565704
[TBL] [Abstract][Full Text] [Related]
9. The cost-effectiveness of a bedaquiline-containing short-course regimen for the treatment of multidrug-resistant tuberculosis in South Africa.
Mpobela Agnarson A; Williams A; Kambili C; Mattson G; Metz L
Expert Rev Anti Infect Ther; 2020 May; 18(5):475-483. PubMed ID: 32186925
[No Abstract] [Full Text] [Related]
10. Latent tuberculosis infection in children: a call for revised treatment guidelines.
Finnell SM; Christenson JC; Downs SM
Pediatrics; 2009 Mar; 123(3):816-22. PubMed ID: 19255008
[TBL] [Abstract][Full Text] [Related]
11. Bedaquiline- versus injectable-containing drug-resistant tuberculosis regimens: a cost-effectiveness analysis.
Ionescu AM; Mpobela Agnarson A; Kambili C; Metz L; Kfoury J; Wang S; Williams A; Singh V; Thomas A
Expert Rev Pharmacoecon Outcomes Res; 2018 Dec; 18(6):677-689. PubMed ID: 30073886
[TBL] [Abstract][Full Text] [Related]
12. Economic evaluation of short treatment for multidrug-resistant tuberculosis, Ethiopia and South Africa: the STREAM trial.
Madan JJ; Rosu L; Tefera MG; van Rensburg C; Evans D; Langley I; Tomeny EM; Nunn A; Phillips PP; Rusen ID; Squire SB;
Bull World Health Organ; 2020 May; 98(5):306-314. PubMed ID: 32514196
[TBL] [Abstract][Full Text] [Related]
13. Impact of reduced hospitalisation on the cost of treatment for drug-resistant tuberculosis in South Africa.
Sinanovic E; Ramma L; Vassall A; Azevedo V; Wilkinson L; Ndjeka N; McCarthy K; Churchyard G; Cox H
Int J Tuberc Lung Dis; 2015 Feb; 19(2):172-8. PubMed ID: 25574915
[TBL] [Abstract][Full Text] [Related]
14. Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: A mathematical modeling analysis.
James LP; Klaassen F; Sweeney S; Furin J; Franke MF; Yaesoubi R; Chesov D; Ciobanu N; Codreanu A; Crudu V; Cohen T; Menzies NA
PLoS Med; 2024 May; 21(5):e1004401. PubMed ID: 38701084
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of novel first-line treatment regimens for tuberculosis.
Owens JP; Fofana MO; Dowdy DW
Int J Tuberc Lung Dis; 2013 May; 17(5):590-6. PubMed ID: 23575322
[TBL] [Abstract][Full Text] [Related]
16. Impact of adverse drug reactions on the incremental cost-effectiveness of bedaquiline for drug-resistant tuberculosis.
Schnippel K; Firnhaber C; Page-Shipp L; Sinanovic E
Int J Tuberc Lung Dis; 2018 Aug; 22(8):918-925. PubMed ID: 29991402
[TBL] [Abstract][Full Text] [Related]
17. Estimating the impact of a novel drug regimen for treatment of tuberculosis: a modeling analysis of projected patient outcomes and epidemiological considerations.
Kendall EA; Malhotra S; Cook-Scalise S; Denkinger CM; Dowdy DW
BMC Infect Dis; 2019 Sep; 19(1):794. PubMed ID: 31500572
[TBL] [Abstract][Full Text] [Related]
18. Direct costs of managing adverse drug reactions during rifampicin-resistant tuberculosis treatment in South Africa.
Schnippel K; Firnhaber C; Berhanu R; Page-Shipp L; Sinanovic E
Int J Tuberc Lung Dis; 2018 Apr; 22(4):393-398. PubMed ID: 29562986
[TBL] [Abstract][Full Text] [Related]
19. Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection.
Holland DP; Sanders GD; Hamilton CD; Stout JE
Am J Respir Crit Care Med; 2009 Jun; 179(11):1055-60. PubMed ID: 19299495
[TBL] [Abstract][Full Text] [Related]
20. Cost and cost-effectiveness of tuberculosis treatment shortening: a model-based analysis.
Gomez GB; Dowdy DW; Bastos ML; Zwerling A; Sweeney S; Foster N; Trajman A; Islam MA; Kapiga S; Sinanovic E; Knight GM; White RG; Wells WA; Cobelens FG; Vassall A
BMC Infect Dis; 2016 Dec; 16(1):726. PubMed ID: 27905897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
